Thromb Haemost 2021; 121(07): 923-930
DOI: 10.1055/a-1326-5110
Cellular Haemostasis and Platelets

On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome

1  Intensive care Unit, Department of Cardiology, Assistance publique des hopitaux de Marseille, Hôpital Nord, Aix Marseille University, Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Marseille, France
,
1  Intensive care Unit, Department of Cardiology, Assistance publique des hopitaux de Marseille, Hôpital Nord, Aix Marseille University, Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Marseille, France
,
2  Institute of Cardiometabolism And Nutrition, INSERM UMRS_1166, GRC 27 GRECO, Sorbonne Université, Paris, France
3  Department of Haematology, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
,
Thomas Cuisset
4  Department of Cardiology, CHU Timone, Marseille, France
,
Caroline Gouarne
1  Intensive care Unit, Department of Cardiology, Assistance publique des hopitaux de Marseille, Hôpital Nord, Aix Marseille University, Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Marseille, France
3  Department of Haematology, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
,
Bernard Jouve
5  Department of Cardiology, Hospital of Aix-en-Provence, F-13100 Aix-en-Provence, France
,
Gilles Lemesle
6  USIC et Centre Hémodynamique, Institut Cœur Poumon, Centre Hospitalier Universitaire de Lille, Lille, France
7  Faculté de Médecine de l'Université de Lille, Lille, France
8  INSERM UMR 1011, Institut Pasteur de Lille, Lille, France
9  FACT (French Alliance for Cardiovascular Trials), Paris, France
,
Franck Paganelli
1  Intensive care Unit, Department of Cardiology, Assistance publique des hopitaux de Marseille, Hôpital Nord, Aix Marseille University, Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Marseille, France
,
Marie-Christine Alessi
10  Centre for CardioVascular and Nutrition Research (C2VN), INSERM 1263, INRA 1260, Marseille, France
,
Julien Mancini
11  Assistance Publique-Hôpitaux de Marseille, INSERM, IRD, SESSTIM, CHU Timone, Department of Public Health (BIOSTIC), Aix Marseille Université, Marseille, France
,
Laurent Bonello
1  Intensive care Unit, Department of Cardiology, Assistance publique des hopitaux de Marseille, Hôpital Nord, Aix Marseille University, Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Marseille, France
› Author Affiliations
Funding This study was funded by a research grant from AstraZeneca.

Abstract

Background A strong association between on-thienopyridine platelet reactivity (PR) and the risk of both thrombotic and bleeding events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) has been demonstrated. However, no study has analyzed the relationship between on-ticagrelor PR and clinical outcome in this clinical setting.

Objectives We aimed to investigate the relationship between on-ticagrelor PR, assessed by the vasodilator-stimulated phosphoprotein (VASP) index, and clinical outcome in patients with ACS undergoing PCI.

Methods We performed a prospective, multicenter, observational study of patients undergoing PCI for ACS. PR was measured using the VASP index following ticagrelor loading dose. The primary study endpoint was the rate of Bleeding Academic Research Consortium (BARC) type ≥2 at 1 year. The key secondary endpoint was the rate of major adverse cardiovascular events (MACE) defined as the composite of cardiovascular death, myocardial infarction, stroke, and urgent revascularization.

Results We included 570 ACS patients, among whom 33.9% had ST-elevation myocardial infarction. BARC type ≥2 bleeding occurred in 10.9% and MACE in 13.8%. PR was not associated with BARC ≥2 or with MACE (p = 0.12 and p = 0.56, respectively). No relationship between PR and outcomes was observed, neither when PR was analyzed quantitatively nor when it was analyzed qualitatively (low on-treatment PR [LTPR] vs. no LTPR).

Conclusion On-ticagrelor PR measured by the VASP was not associated with bleeding or thrombotic events in ACS patients undergoing PCI. PR measured by the VASP should not be used as a surrogate endpoint in studies on ticagrelor.

Supplementary Material



Publication History

Received: 23 September 2020

Accepted: 25 November 2020

Publication Date:
01 December 2020 (online)

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany